Moderna (MRNA) Reports Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Spain's ex-transport minister sentenced to 24 years for corruption
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Moderna Announces Positive Interim Phase 1 Data for mRNA Flu Vaccine and Provides Program Update
December 10, 2021 7:00 AM ESTPhase 1 study of quadrivalent flu vaccine (mRNA-1010) successfully boosted titers against all four strains in older and younger adults, even at lowest dose; no significant safety concerns were observed
Phase 2 dose-confirmation study was fully enrolled in November (N=500); preparation for Phase 3 study underway
Seasonal flu program now moving beyond quadrivalent: announcing mRNA-1011 & mRNA-1012 development candidates
Conference call to be held today at 8:00 a.m. ET
CAMBRIDGE, Mass.--(BUSINESS... More
